¡¾µ÷¼Á¡¿±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2024Äê16¸öרҵ½ÓÊܵ÷¼Á
²é¿´: 508  |  »Ø¸´: 1
±¾Ìû²úÉú 1 ¸ö ·­ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴

ÑîµÂÁ¼

½ð³æ (СÓÐÃûÆø)

[ÇóÖú] ÕªÒª·­ÒëÇóÖú

¡¾ÕªÒª¡¿Ä¿µÄ£ºÍ¨¹ý¶Ô¶àÎ÷×Ïɼ´¼µÄѪҩŨ¶È¼ì²â£¬Ì½¾¿ÆäҩʱÇúÏßÏÂÃæ»ý£¨AUC£©Ó붾ÐԺͽüÆÚÁÆЧµÄ¹Øϵ£¬³õ²½È·Á¢¶àÎ÷×Ïɼ´¼µÄÖÎÁÆ´°AUC·¶Î§¡£·½·¨£º167ÀýʵÌåÁö»¼Õߣ¬½ÓÊܺ¬¶àÎ÷×Ïɼ´¼Ò©ÎïµÄ3ÖÜÖÎÁÆ·½°¸£¬²É¼¯µÎ×¢½áÊøÇ°10minÖÁ½áÊøºÍµÎ×¢½áÊøºó30-60minµÄѪÑù£¬²â¶¨ÆäѪҩŨ¶È²¢¼ÆËãAUCÖµ¡£Í³¼Æ·ÖÎö¶àÎ÷×Ïɼ´¼AUCÖµÓëÖÐÐÔÁ£Ï¸°û¼õÉÙ·¢ÉúÂʵÄÏà¹ØÐÔ£¬ÒÔ¼°AUCÖµ½üÆÚÁÆЧµÄÏà¹ØÐÔ¡£½á¹û£º167Àý»¼Õߣ¬¶àÎ÷×Ïɼ´¼AUCÖµ·Ö²¼Îª0.5-4.1mg.h/L£¬AUCƽ¾ùֵΪ1.6 mg.h/L£¬±äÒìϵÊýΪ41.35%¡£·¢Éú3¼¶¼°ÒÔÉÏÖÐÐÔÁ£Ï¸°û¼õÉÙ»¼Õߣ¨17Àý£©µÄAUCÖµ´óÓÚ2.7 mg.h/L£¬Óë3¼¶ÒÔÏÂÖÐÐÔÁ£Ï¸°û¼õÉÙ»¼Õߣ¨150Àý£©Ïà±ÈPÖµµÈÓÚ0.00¡£¶àÎ÷×Ïɼ´¼AUCÖµ£¾1.5 mg.h/LµÄÁÙ´²»ñÒæÂÊ£¨80.8%£©Ó룼1.5 mg.h/LµÄÁÙ´²»ñÒæÂÊ£¨0%£©Ïà±È£¬P=0.00¡£½áÂÛ£º¶àÎ÷×Ïɼ´¼µÄAUCÖµ1.5-2.7 mg.h/L£¬¿ÉÒÔ×÷Ϊ¶àÎ÷×Ïɼ´¼ÁÙ´²²Î¿¼µÄÒ©´ú¶¯Á¦Ñ§ÖÎÁÆ´°¡£
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Î人һÐÄÒ»Òë

¾èÖú¹ó±ö (ÖøÃûдÊÖ)


¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ...
ÑîµÂÁ¼: ½ð±Ò+70, ·­ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2018-03-06 01:19:54
¡¾ÕªÒª¡¿Ä¿µÄ£ºÍ¨¹ý¶Ô ¶àÎ÷×Ïɼ´¼ µÄ ѪҩŨ¶È¼ì²â£¬Ì½¾¿Æä ҩʱÇúÏßÏÂÃæ»ý£¨AUC£©Óë ¶¾ÐÔ ºÍ ½üÆÚÁÆЧ µÄ¹Øϵ£¬³õ²½È·Á¢¶àÎ÷×Ïɼ´¼µÄÖÎÁÆ´°AUC·¶Î§¡£·½·¨£º167Àý ʵÌåÁö»¼Õߣ¬½ÓÊÜ º¬¶àÎ÷×Ïɼ´¼Ò©Îï µÄ 3ÖÜÖÎÁÆ·½°¸£¬²É¼¯ µÎ×¢½áÊø Ç°10min ÖÁ½áÊø ºÍ µÎ×¢½áÊøºó 30-60minµÄѪÑù£¬²â¶¨Æä ѪҩŨ¶È ²¢¼ÆËãAUCÖµ¡£Í³¼Æ·ÖÎö¶àÎ÷×Ïɼ´¼AUCÖµ Óë ÖÐÐÔÁ£Ï¸°û¼õÉÙ·¢ÉúÂÊ µÄÏà¹ØÐÔ£¬ÒÔ¼°AUCÖµ½üÆÚÁÆЧµÄÏà¹ØÐÔ¡£½á¹û£º167Àý»¼Õߣ¬¶àÎ÷×Ïɼ´¼AUCÖµ·Ö²¼Îª0.5-4.1mg.h/L£¬AUCƽ¾ùֵΪ1.6 mg.h/L£¬±äÒìϵÊýΪ41.35%¡£·¢Éú3¼¶¼°ÒÔÉÏ ÖÐÐÔÁ£Ï¸°û¼õÉÙ»¼Õߣ¨17Àý£©µÄAUCÖµ ´óÓÚ2.7 mg.h/L£¬Óë3¼¶ÒÔÏÂÖÐÐÔÁ£Ï¸°û¼õÉÙ »¼Õߣ¨150Àý£©Ïà±ÈPÖµµÈÓÚ0.00¡£¶àÎ÷×Ïɼ´¼AUCÖµ£¾1.5 mg.h/LµÄÁÙ´²»ñÒæÂÊ£¨80.8%£©Ó룼1.5 mg.h/LµÄÁÙ´²»ñÒæÂÊ£¨0%£©Ïà±È£¬P=0.00¡£½áÂÛ£º¶àÎ÷×Ïɼ´¼µÄAUCÖµ1.5-2.7 mg.h/L£¬¿ÉÒÔ×÷Ϊ ¶àÎ÷×Ïɼ´¼ ÁÙ´²²Î¿¼µÄ Ò©´ú¶¯Á¦Ñ§ÖÎÁÆ´°¡£
Abstract: Purpose: through detecting the plasma concentration of docetaxel, we explored the correlation between short-term effect and AUC(area under the curve) & toxicity of docetaxel, and established inital therapeutic window AUC range of docetaxel. Method: 167 patients with solid tumor were selected as research objects and subjected to 3 weeks of docetaxel drug treatment. After that the blood sample from 10 min before ending docetaxel infusion to infusion ending point as well as the blood sample from 30 to 60 min after ending docetaxel infusion were collected for measuring plasma concentration of docetaxel and calculating AUC value. Statistical analysis was conducted to investigate the correlation between docetaxel AUC value and neutropenia incidence rate as well as the corealtion between AUC value and short-term effect. Results: for the 167 patients, docetaxel AUC value ranged from 0.5 to 4.1mg.h/L, averaging at 1.6 mg.h/L, with variable coefficient of 41.35%. There were 17 patients showing grade-3 or above neutropenia, with AUC value over 2.7 mg.h/L; there were 150 patients showing grade-3 or below neutropenia. In comparison of AUC value between the two groups, p=0.00. In comparison of clinical benefit rate (80.8%) upon docetaxel AUC £¾1.5 mg.h/L and that upon docetaxel AUC £¼1.5 mg.h/L, it could be found that p value is equal to 0. Conclusion: The docetaxel AUC value of 1.5-2.7 mg.h/L can be adopted as referential pharmacokinetic therapeutic window for docetaxel clinical treatment.
2Â¥2018-03-05 11:44:27
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌøת ÎÒÒª¶©ÔÄÂ¥Ö÷ ÑîµÂÁ¼ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍƼö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[»ù½ðÉêÇë] Ìرð×ÊÖúÉóºË״̬ +7 pantray 2024-04-17 8/400 2024-04-20 11:40 by wolfgangHugh
[¿¼ÑÐ] ÏëÎÊÒ»ÏÂÓÐûÓÐÐèÒªÎÄÕµ«ÊÇûʱ¼ä´øѧÉúµÄÑо¿Éúµ¼Ê¦¡£ +11 lekinna 2024-04-19 21/1050 2024-04-20 10:29 by °²Ð¡Ó£
[ÂÛÎÄͶ¸å] ±à¼­·µ¸åÈøĸñʽ£¬Õâ¸öʱºòÄÜ´óÐÞÄÚÈÝÂ𣿠+3 Ë«±¶ºÃÔ˽õÀð 2024-04-17 4/200 2024-04-20 09:54 by wuyuanzhao
[ÕÒ¹¤×÷] ÊÂÒµµ¥Î»»¹ÊÇ´óѧºÃ£¿ +18 ÇàƼ֮ĭ 2024-04-16 19/950 2024-04-20 08:46 by С³½×Ó
[ÂÛÎÄͶ¸å] ×î½üÓöµ½ÕâÑùÒ»¸öÎÊÌâ 2+4 asd123gfa689 2024-04-18 10/500 2024-04-19 18:57 by asd123gfa689
[¿¼ÑÐ] ¿¼ÑÐÓ¢Óï´øѧ +6 choice666 2024-04-18 6/300 2024-04-19 17:46 by charles-c
[¿¼²©] 24/25¶Á²©Ç󲩵¼ +4 ±¦23 2024-04-16 4/200 2024-04-19 17:18 by wangzhe_bs
[½Ìʦ֮¼Ò] ÃÀ¹ú½ÌÊÚ¿ª³ýÖйúÑо¿Éú£ºÎҾͲ»¸Ã¼ȡÄ㣡 +7 ËÕ¶«Æ¶þÊÀ 2024-04-15 7/350 2024-04-19 16:20 by feng6531
[»ù½ðÉêÇë] ÏÂÓêÁË +13 zju2000 2024-04-16 19/950 2024-04-19 09:24 by duxin_30
[¿¼ÑÐ] ±¾¿Æ211 277·ÖÇóµ÷¼Á +3 0854ͨÐŹ¤³Ì 2024-04-18 4/200 2024-04-18 09:11 by »¨»¨Æ½Í·¸ç
[²©ºóÖ®¼Ò] ²©ºó½øÕ¾ÄêÁä¿ÉÒÔ³¬¹ý35Ëꣿ +8 suesong0818 2024-04-14 8/400 2024-04-18 08:38 by charles-c
[¿¼ÑÐ] 274Çóµ÷¼Á +7 Ëĸö´ó×Ö£¬ÄãµÎº 2024-04-14 10/500 2024-04-17 22:38 by »ª±±Áõ±ø
[ÂÛÎÄͶ¸å] ¿ÉÒÔ´òµç»°Îʱ༭²¿ÊÇ·ñ¿ÉÒÔÏÈ·¢Â¼ÓÃ֪ͨÂð +7 Ë«±¶ºÃÔ˽õÀð 2024-04-14 10/500 2024-04-17 13:38 by cjzhu
[»ù½ðÉêÇë] ÇëÎʽÌÓý²¿ÈËÎÄÉç¿ÆÄѶȴóÂð +9 ½õÒÂÎÀº®Õ½ 2024-04-15 14/700 2024-04-16 23:10 by ½õÒÂÎÀº®Õ½
[¿¼ÑÐ] ÍÁľ¹¤³Ì281Çóµ÷¼Á +4 ÇÇÙâľ 2024-04-13 4/200 2024-04-16 21:40 by zjl½¥Ðн¥Ô¶
[¿¼ÑÐ] 329Çóµ÷¼Á +6 Kaylawander 2024-04-13 7/350 2024-04-16 12:00 by ·çÀ´»¨¿ª1
[¿¼ÑÐ] 296Çóµ÷¼Á +3 Cclocomotive 2024-04-16 4/200 2024-04-16 10:04 by 19862091
[¿¼ÑÐ] »¯Ñ§¡¢²ÄÁÏÀà×îºóµ÷¼Á»ú»á£¡£¡£¡ +3 ¼ÓÓÍŬÁ¦¾ÍºÃ 2024-04-14 10/500 2024-04-15 09:05 by ÈÎpen
[¿¼ÑÐ] 287Çóµ÷¼Á +6 ÄÏ›h 2024-04-14 6/300 2024-04-14 23:08 by lincunhui
[¿¼ÑÐ] 278Çóµ÷¼Á +4 ÔÂÁÁ¾ÍËâ 2024-04-13 5/250 2024-04-14 23:03 by ÓÀ×ÖºÅ
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û